Coagulation factor IX
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Coagulation factor IX as ChEMBL target CHEMBL2016, mapped to UniProt P00740. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Coagulation factor IX matters
Coagulation factor IX is reviewed as Coagulation factor IX (UniProt P00740); Coagulation factor IX shows approved-linked disease relevance led by hemophilia B. 5 more disease programs remain visible in the same review block.; 8 linked drugs keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 1260 compounds, and 96 assays, with lead potency reaching pChEMBL 10.5.
Coagulation factor IX Sequence length is 461 aa.
Review this target as Coagulation factor IX, mapped to UniProt P00740. Sequence length is 461 aa.
Protein source · UniProt accession via ChEMBL component mappingCoagulation factor IX shows approved-linked disease relevance led by hemophilia B. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALBUTREPENONACOG ALFA, COAGULATION FACTOR IX HUMAN, COAGULATION FACTOR IX RECOMBINANT HUMAN.
Start review with hemophilia B because it currently carries approved-linked support. Linked drugs include ALBUTREPENONACOG ALFA, COAGULATION FACTOR IX HUMAN, COAGULATION FACTOR IX RECOMBINANT HUMAN, EFTRENONACOG ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 0 approved drugs, 1260 compounds, and 96 assays for this target. The dominant activity type is KI. CHEMBL4107149 is the current potency anchor at pChEMBL 10.5.
Use CHEMBL4107149 as the tractability anchor when discussing potency (pChEMBL 10.5).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Coagulation factor IX matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P00740, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need to see why hemophilia B is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4107149
|
10.5 | Ki | — |
|
|
No preferred name
CHEMBL4110926
|
10.4 | Ki | — |
|
|
No preferred name
CHEMBL4114881
|
10.3 | Ki | — |
|
|
No preferred name
CHEMBL4112773
|
10.3 | Ki | — |
|
|
No preferred name
CHEMBL4113483
|
10.2 | Ki | — |